English
Alivus Life Sciences Q3 Results
- BSE: 543322
- NSE: ALIVUS
- ISIN: INE03Q201024
- Sector: Biotechnology & Drugs
BSE
908.45
16.80 (1.88%)
16.80 (1.88%)Volume12.63 K
Updated: Fri 7 Nov, 2025 | 15:29:48
NSE
915.0524.55 (2.76%)
24.55 (2.76%)Volume1.58 L
Updated: Fri 7 Nov, 2025 | 15:44:15
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Alivus Life Sciences Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 24 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 466.70 | 387.61 | 20.40% | 413.43 | 12.89% |
| Depreciation/ Amortization | 15.16 | 15.09 | 0.44% | 13.18 | 15.04% |
| Operating Income | 175.15 | 119.27 | 46.86% | 159.38 | 9.89% |
| Net Income | 136.96 | 95.32 | 43.69% | 118.77 | 15.32% |
| Other Operating Expenses Total | 100.57 | 84.89 | 18.48% | 87.00 | 15.60% |
| Net Income Before Taxes | 185.15 | 127.46 | 45.26% | 160.68 | 15.23% |
| Total Revenue | 641.84 | 506.88 | 26.63% | 572.80 | 12.05% |
| Selling/ General/ Admin Expenses Total | 65.69 | 62.44 | 5.21% | 71.05 | -7.55% |
| Diluted Normalized EPS | 11.14 | 7.75 | 43.74% | 9.67 | 15.20% |